NASDAQ: LBRX · Life Sciences · 3 alerts · CIK 1691082
Share price
$42.99Close, Nov 16
Market cap
$1.39B
Shares outstanding
32.36MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Lb Pharmaceuticals Inc filings on SEC EDGAR ↗
LB Pharmaceuticals Inc. reported continued clinical development of its lead candidate, LB-102, for the treatment of schizophrenia. The company recorded a net loss for the quarter, typical for a clinical-stage biopharmaceutical firm, with research and development expenses remaining the primary driver of cash outflow.
LB Pharmaceuticals reported third quarter 2026 financial results, highlighting a cash position of $403.8 million following a $150 million private placement. The company remains on track for a Phase 3 topline data readout for its lead schizophrenia candidate, LB-102, in the first half of 2027.
“We recently strengthened our leadership team with the appointments of Dr. Susan Kozauer as Chief Medical Officer and Joe Miller as Chief Financial Officer, adding two highly accomplished executives whose expertise is directly aligned with our next phase of growth as we advance LB-102 across multiple neuropsychiatric indications and prepare for potential commercialization in schizophrenia.”
Heather Turner, Chief Executive Officer of LB Pharmaceuticals
“Our recent R&D Day highlighted why we believe LB-102 has the potential to become the branded antipsychotic of choice, based on a differentiated profile with the potential to balance efficacy, tolerability, and simplicity of use.”
Heather Turner, Chief Executive Officer of LB Pharmaceuticals